Lonza, OncoMed to Collaborate on Anti-Cancer Therapeutics
Lonza and OncoMed Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed's pipeline of anti-cancer stem cell therapeutics.
Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS SystemLicense provides access to Lonza's GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.
OncoMed's pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells.